Literature DB >> 6380596

Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review.

G Aubel-Sadron, D Londos-Gagliardi.   

Abstract

Daunorubicin and doxorubicin, two antibiotics belonging to the anthracycline group, are widely used in human cancer chemotherapy. Their activity has been attributed mainly to their intercalation between the base pairs of native DNA. Complex formation between daunorubicin or doxorubicin with polydeoxyribonucleotides and DNAs of various base composition or chromatins has been investigated by numerous techniques. Many authors have tried to correlate biological and therapeutic activities with the affinity of the drugs for DNA or some specific sequences of DNA. In vivo these anthracycline drugs cause DNA damage such as fragmentation and single-strand breaks. The mechanism of action of anthracyclines involves the inhibition of RNA and DNA syntheses. There exists two limiting factors in the use of anthracyclines as antitumoral agents: a chronic or acute cardiotoxicity and a spontaneous or acquired resistance. In both cases, there is probably an action at the membrane level. It has to be noted that daunorubicin and doxorubicin have a particular affinity for phospholipids and that the development of resistance is linked to some membrane alterations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6380596     DOI: 10.1016/0300-9084(84)90018-x

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  45 in total

1.  Correlation between anthracycline structure and human DNA ligase inhibition.

Authors:  G Ciarrocchi; M Lestingi; M Fontana; S Spadari; A Montecucco
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

2.  Identification of binding mechanisms in single molecule-DNA complexes.

Authors:  Rainer Eckel; Robert Ros; Alexandra Ros; Sven David Wilking; Norbert Sewald; Dario Anselmetti
Journal:  Biophys J       Date:  2003-09       Impact factor: 4.033

Review 3.  Activating secondary metabolism with stress and chemicals.

Authors:  Vanessa Yoon; Justin R Nodwell
Journal:  J Ind Microbiol Biotechnol       Date:  2013-12-11       Impact factor: 3.346

4.  A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.

Authors:  Sarah F Adams; Evelyn B Marsh; Wafic Elmasri; Steffanie Halberstadt; Stephanie Vandecker; Mary D Sammel; Angela R Bradbury; Mary Daly; Beth Karlan; Stephen C Rubin
Journal:  Gynecol Oncol       Date:  2011-09-25       Impact factor: 5.482

5.  A tunable assay for modulators of genome-destabilizing DNA structures.

Authors:  Imee M A Del Mundo; Eun Jeong Cho; Kevin N Dalby; Karen M Vasquez
Journal:  Nucleic Acids Res       Date:  2019-07-26       Impact factor: 16.971

Review 6.  Streptomycetes producing daunomycin and related compounds: do we know enough about them after 25 years?

Authors:  J Huk; M Blumauerova
Journal:  Folia Microbiol (Praha)       Date:  1989       Impact factor: 2.099

7.  Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients.

Authors:  Daniel S Oh; Maggie C U Cheang; Cheng Fan; Charles M Perou
Journal:  Radiat Res       Date:  2014-02-14       Impact factor: 2.841

8.  Survival of rat mammary tumor cell clones and DNA strand damage following adriamycin treatment.

Authors:  D P Evans; R E Meyn; S P Tomasovic
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 9.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

Review 10.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.